$GILD (Gilead Sciences Inc.)

$GILD {{ '2016-02-02T08:50:49+0000' | timeago}} • Announcement

Biopharmaceutical company $GILD said it has promoted its current SVP of Human Resources, Katie Watson, to EVP of Human Resources.

$GILD {{ '2017-10-19T16:10:20+0000' | timeago}} • Announcement

$GILD received approval from the US FDA for Yescarta, a new gene therapy developed by Kite Pharma for the treatment of adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments. Yescarta is a CAR-T therapy, which reprograms the body’s own immune cells to recognize and attack malignant cells.

$GILD {{ '2017-10-17T16:06:03+0000' | timeago}} • Announcement

$GILD announced the promotion of Alessandro Riva, MD, to EVP, Oncology Therapeutics, with responsibility for the company’s hematology and oncology programs, including cell therapy research and development.

$GILD {{ '2017-10-04T14:22:07+0000' | timeago}} • Announcement

$GILD announced results from a Phase 3 study evaluating the efficacy of a fixed-dose combination of bictegravir (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (FTC/TAF), a dual-NRTI backbone in HIV-1-infected patients. The study found BIC/FTC/TAF to be superior to other regimens.

$GILD {{ '2017-10-04T13:59:54+0000' | timeago}} • Announcement

$GILD has also expanded its licensing agreements with Sun Pharmaceutical Industries Limited, Strides Shasun Limited, Mylan Laboratories Limited and SeQuent Scientific Limited to include BIC, and products incorporating the compound, for distribution in 116 developing countries.

$GILD {{ '2017-10-04T13:59:38+0000' | timeago}} • Announcement

$GILD announced a new licensing agreement with the Medicines Patent Pool (MPP) to expand access to bictegravir (BIC) upon regulatory approval in the US. BIC is used to treat HIV-1 infection. MPP can sub-license rights to BIC to companies in India, China and South Africa to manufacture therapies containing BIC for distribution in 116 countries.

$GILD {{ '2017-09-27T21:15:40+0000' | timeago}} • Announcement

$GILD announced that Kevin Young CBE, COO, plans to retire, effective early 2018. Mr. Young will remain with $GILD through 1Q18 and in an advisory capacity thereafter.

$GILD {{ '2017-09-26T13:43:32+0000' | timeago}} • Announcement

$GILD and $KITE announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to $GILD’s cash tender offer for $KITE expired on September 25, 2017. With the expiration of the waiting period, the tender offer is expected to close in the beginning of October 2017, subject to closing conditions.

$GILD {{ '2017-09-25T12:54:53+0000' | timeago}} • Announcement

$GILD said that the China Food and Drug Administration has approved Sovaldi,  a once-daily oral inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Sovaldi is the first Gilead HCV medicine approved in China. Sovaldi received marketing approval from the US FDA in 2013 and the European Commission in 2014.

$GILD {{ '2017-09-15T13:21:02+0000' | timeago}} • Announcement

$GILD announced the pricing of senior unsecured notes in an aggregate principal amount of $3Bil, in an underwritten, registered public offering. The offering is expected to close September 21, 2017, subject to customary closing conditions. $GILD intends to use the net proceeds from the offering to finance a portion of the Kite acquisition.

$GILD {{ '2017-08-28T14:12:29+0000' | timeago}} • Announcement

$GILD agreed to acquire $KITE for $180 per share in cash, or approx. $11.9Bil in total. The deal is expected to close in 4Q17, and is expected to be neutral to earnings by year three and accretive thereafter. $GILD plans to finance the transaction with a combination of cash on hand, bank debt and senior unsecured notes.

$GILD {{ '2017-08-02T13:17:21+0000' | timeago}} • Announcement

$GILD announced that the US FDA has approved updated labeling for Epclusa, an all-oral, pan-genotypic, once-daily single tablet regimen for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.

$GILD {{ '2017-07-27T19:17:21+0000' | timeago}} • Webcast

$GILD stated that for Genvoya, it is starting to see performance trends similar to that of the US in other countries like Germany. The company is seeing good uptake in Spain and Italy. France has also done extraordinarily well in just four months to become the leading naïve and switch product.

$GILD {{ '2017-07-27T19:04:57+0000' | timeago}} • Webcast

For HCV, $GILD’s total revenues in the US were $1.9Bil in 2Q17, down 17% YoY and up 13% sequentially. The QoQ increase was primarily due to a change in inventory and the timing of patient starts. In Europe, total HCV revenue was $591MM, down 24% YoY and up 21% from 1Q17.

$GILD {{ '2017-07-27T19:00:11+0000' | timeago}} • Webcast

$GILD is seeing strong uptake of its TAF-based regimens in the US and Europe. In the US, total HIV and HBV revenues were $2.6Bil for 2Q17, up 19% YoY and up 10% sequentially. In Europe, total HIV and HBV revenues were $732MM, down 3% YoY and up 5% sequentially. The YoY decrease was driven by negative foreign exchange.

$GILD {{ '2017-07-27T18:32:52+0000' | timeago}} • Announcement

$GILD declared a cash dividend of $0.52 per share of common stock for 3Q17, payable on September 28, 2017, to stockholders of record on September 15, 2017.

$GILD {{ '2017-07-26T21:10:46+0000' | timeago}} • Infographic

$GILD Gilead Sciences Earnings AlphaGraphic: Q2 2017 Highlights

$GILD {{ '2017-07-26T20:37:51+0000' | timeago}} • Announcement

$GILD revised its FY17 guidance. The company now expects net product sales to be $24-25.5Bil in FY17. Non-HCV product sales are expected to be $15.5-16Bil while HCV product sales are expected to be $8.5-9.5Bil. Adjusted product gross margin is expected to be 86-88% in FY17.

$GILD {{ '2017-07-26T20:33:53+0000' | timeago}} • Announcement

$GILD's total product sales for 2Q17 were $7Bil compared to $7.7Bil for 2Q16. Product sales were $5Bil in the US, $1.4Bil in Europe and $665MM in other locations during 2Q17. Antiviral product sales were $6.4Bil and Other product sales were $607MM for 2Q17.

$GILD {{ '2017-07-26T20:29:32+0000' | timeago}} • Announcement

$GILD posted a slight decrease in 2Q17 results. Net income was $3.1Bil or $2.33 per share compared to $3.5Bil or $2.58 per share in 2Q16. Adjusted net income was $3.4Bil or $2.56 per share in 2Q17. Total revenues were $7.1Bil compared to $7.8Bil in the prior-year period.

$GILD {{ '2017-07-24T13:41:56+0000' | timeago}} • Announcement

$GILD announced results from two Phase 3 studies evaluating the efficacy and safety of a fixed-dose combination of bictegravir (BIC) and emtricitabine/tenofovir alafenamide (FTC/TAF) for the treatment of HIV-1 infection in treatment-naïve adults. This regimen has been well tolerated with low rates of discontinuations due to adverse events.

Recent Transcripts

PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, August 9 2017 - 9:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
TECH (Bio-Techne Corp.)
Tuesday, August 8 2017 - 1:00pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
RGEN (Repligen Corporation)
Thursday, August 3 2017 - 12:31pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
INSM (Insmed Incorporated)
Thursday, August 3 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
BTX (BioTime, Inc.)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
ILMN (Illumina Inc.)
Tuesday, August 1 2017 - 8:30pm
SGEN (Seattle Genetics, Inc.)
Thursday, July 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm

AlphaGraphics you may like